The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Haloperidol alone or in combination for acute mania
Open accessAbstract
BACKGROUND: The main objectives in treating mania are to control dangerous behaviour, reduce suicide, produce appropriate acute sedation and shorten the episode of mood disturbance. Among different drugs, haloperidol has for many years been used in treating psychotic patients, but it has a troublesome side effect profile. OBJECTIVES: To assess the effects of haloperidol for the treatment of mania in comparison with placebo or other active drugs, either as monotherapy or add-on treatment. SEARCH STRATEGY: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (11 October 2005), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2005), MEDLINE (1966-2003), EMBASE (1980-2003), CINAHL (1982-2003), PsycINFO (1872-2003) and reference lists. We also contacted experts, triallists and pharmaceutical companies in the field. SELECTION CRITERIA: Randomised trials comparing haloperidol with placebo or other active treatment in the treatment of acute manic or mixed episodes in patients with bipolar disorder or schizoaffective disorder. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information. We collected adverse effects information from the trials. MAIN RESULTS: Fifteen trials involving 2022 people were included. Compared to placebo, haloperidol was more effective at reducing manic symptoms, both as monotherapy (Weighted Mean Difference (WMD) -5.85, 95% Confidence Interval (CI) -7.69 to -4.00) and as adjunctive treatment to lithium or valproate (WMD -5.20, 95% CI -9.26 to -1.14). There was a statistically significant difference, with haloperidol being less effective than aripiprazole (Relative Risk (RR) 1.45, 95% CI 1.22 to 1.73). No significant differences between haloperidol and risperidone, olanzapine, carbamazepine or valproate were found. Compared with placebo, a statistically significant difference in favour of haloperidol in failure to complete treatment (RR 0.74, 95% Cl 0.57 to 0.96) was reported. Haloperidol was associated with less weight gain than olanzapine (RR: 0.28, 95% CI 0.12 to 0.67), but with a higher incidence of tremor (RR: 3.01, 95% CI 1.55 to 5.84) and other movement disorders. AUTHORS' CONCLUSIONS: There is some evidence that haloperidol is an effective treatment for acute mania. From the limited data available, there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone. Some evidence suggests that haloperidol could be less effective than aripiprazole. Referring to tolerability, when considering the poor evidence comparing drugs, clinicians and patients should consider different side effect profiles as an important issue to inform their choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
Self-citationOne hundred years of schizophrenia: a meta-analysis of the outcome literature
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1409 · Cited by 762
The epidemiology of DSM-III-R bipolar I disorder in a general population survey
KESSLER, R. C., RUBINOW, D. R., HOLMES, C., ABELSON, J. M., & ZHAO, S. (1997) · Psychological Medicine · doi:10.1017/s0033291797005333 · Cited by 600
CROW, T. J. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.4.531-a · Cited by 556
Handbook of Affective Disorders
Nasrallah, H. A. (1993) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199311000-00026 · Cited by 442
Sachs, G. S., Grossman, F., Ghaemi, S. N., Okamoto, A., & Bowden, C. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1146 · Cited by 424
Cochrane Collaboration Handbook
Mulrow, C. (1996) · Medical Entomology and Zoology · Cited by 403
Historical perspectives and natural history of bipolar disorder
Angst, J., & Sellaro, R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00909-4 · Cited by 395
Neuropsychological functioning of first-episode schizophreniform patients
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.7.898 · Cited by 322
Neuroleptics: Effects on Neuropsychological Function in Chronic Schizophrenic Patients
Cassens, G., Inglis, A. K., Appelbaum, P. S., & Gutheil, T. G. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.3.477 · Cited by 271
Segal, J., Berk, M., & Brook, S. (1998) · PubMed · Cited by 238
A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania
Tohen, M., Goldberg, J. F., Gonzalez-Pinto Arrillaga, A. M., Azorin, J. M., Vieta, E., Hardy-Bayle, M.-C., Lawson, W. B., Emsley, R. A., Zhang, F., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1218 · Cited by 229
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
Sanger, T. M., Lieberman, J. A., Tohen, M., Grundy, S., Beasley, Jr., & Tollefson, G. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.79 · Cited by 215
Smulevich, A. B., Khanna, S., Eerdekens, M., Karcher, K., Kramer, M., & Grossman, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.06.003 · Cited by 192
Pharmacologic agents for the treatment of acute bipolar mania
McElroy, S. L., & Keck, P. E. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00961-6 · Cited by 160
Shopsin, B. (1975) · Archives of General Psychiatry · doi:10.1001/archpsyc.1975.01760190036004 · Cited by 153
Simon, G. E., & Unützer, J. (1999) · Psychiatric Services · doi:10.1176/ps.50.10.1303 · Cited by 144
McElroy, S. L., Keck, P. E., Stanton, S. P., Tugrul, K. C., Bennett, J. A., & Strakowski, S. M. (1996) · PubMed · Cited by 133
Chan, W. C., Lam, L. C. W., Choy, C. N. P., Leung, V., Li, S.-W., & Chiu, H. F. K. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.504 · Cited by 119
A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania
Garfinkel, P. E., Stancer, H. C., & Persad, E. (1980) · Journal of Affective Disorders · doi:10.1016/0165-0327(80)90029-4 · Cited by 112
Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study.
Lenox, R. H., NEWHOUSE, P. A., Creelman, W., & Whitaker, T. M. (1992) · PubMed · Cited by 99
Acute high-dose parenteral haloperidol treatment of psychosis
Lerner, Y., Lwow, E., Levitin, A.-L., & Belmaker, R. H. (1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.8.1061 · Cited by 81
Chouinard, G., Annable, L., Turnier, L., Holobow, N. E., & Szkrumelak, N. (1993) · PubMed · Cited by 73
Potkin, S. G., Thyrum, P. T., Alva, G., Bera, R. B., Yeh, C., & Arvanitis, L. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00004 · Cited by 70
Olanzapineversushaloperidol in the treatment of schizoaffective disorder
Trân, P. V., Tollefson, G. D., Sanger, T. M., Lu, Y., Berg, P. H., & Beasley, C. M. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.174.1.15 · Cited by 69
Shi, L., Namjoshi, M. A., Zhang, F., Gandhi, G., Edgell, E. T., Tohen, M. F., Breier, A. F., & Haro, J. M. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00003 · Cited by 66
Lithium combined with carbamazepine or haloperidol in the treatment of mania.
Small, J. G., Klapper, M. H., Marhenke, J. D., Milstein, V., Woodham, G. C., & Kellams, J. J. (1995) · PubMed · Cited by 56
Carbamazepine Compared to Haloperidol in Acute Mania
BROWN, D., Silverstone, T., & Cookson, J. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198907000-00005 · Cited by 55
Pharmacologic treatment of schizoaffective disorder
Keck, P. E., McElroy, S. L., Strakowski, S. M., & West, S. A. (1994) · Psychopharmacology · doi:10.1007/bf02244982 · Cited by 52
Janicak, P. G., Keck, P. E., Davis, J. M., Kasckow, J., Tugrul, K. C., Dowd, S. M., Strong, J., Sharma, R. P., & Strakowski, S. M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00002 · Cited by 42
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.
McIntyre, R. S. (2002) · PubMed · Cited by 38
Abood, Z., Sharkey, A., Webb, M., Kelly, A., & Gill, M. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01184.x · Cited by 36
Clonazepam in acute and maintenance treatment of bipolar affective disorder.
Chouinard, G. (1987) · PubMed · Cited by 35
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type
Tohen, M. F., Zhang, F., Keck, P. E., Feldman, P. D., Risser, R. C., Trân, P. V., & Breier, A. F. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00303-7 · Cited by 29
Symptomatic predictors of ECT response in medication-nonresponsive manic patients.
Schnur, D. B., Mukherjee, S., Sackeïm, H. A., Lee, C., & Roth, S. D. (1992) · PubMed · Cited by 22
P.2.133 Quetiapine vs placebo for acute mania associated with bipolar disorder (STAMP 1)
Brecher, M., & Huizar, K. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92086-4 · Cited by 13
Pretreatment plasma HVA and haloperidol response in acute mania
Chou, J. C.-Y., Czobor, P., Tuma, I., Charles, O., Bebe, R., Cooper, T. B., Chang, W., Lane, H., & Stone, D. L. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00134-2 · Cited by 12
Spießl, H., Hübner‐Liebermann, B., & Cording, C. (2002) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-2002-33055 · Cited by 10
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Yatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder
Berk, M., Dodd, S., Kauer‐Sant’Anna, M., Malhi, G. S., Bourin, M., Kapczinski, F., & Norman, T. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01058.x · Cited by 396
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Aripiprazole monotherapy in the treatment of bipolar disorder: A meta-analysis
Fountoulakis, K. N., Vieta, E., & Schmidt, F. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.10.018 · Cited by 52
“73) which in turn was equal to olanzapine and risperidone (Cipriani et al., 2006).”
Background
Metadata
- Authors
- Cipriani, A., Rendell, J. M., & Geddes, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-07-19
- Volume
- 2010
- Issue
- 1
- Pages
- CD004362-CD004362
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1583959265
- Cited by
- 285
- References
- 41
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.